Memòria 2010 - IISPV

Àmbit estratègic 3. Oncologia i hematologiaLARRAÑAGA N, GALCERAN J, ARDANAZ E, FRANCHP, NAVARRO C, SÁNCHEZ MJ, PASTOR-BAR-RIUSO R, FOR THE PROSTATE CANCER WORKINGGROUP. Prostate Cancer Incidence Trendsin Spain around the PSA era: impact onmortality. Ann Oncol. 2010; 21:83-9. FI:5,647. 1r quartil.PERIS-BONET R, SALMERÓN D, MARTÍNEZ-BENEITOMA, GALCERAN J, MARCOS-GRAGERA R, FELIPES, GONZÁLEZ V, SÁNCHEZ DE TOLEDO CODINAFOR THE SPANISH CHILDHOOD CANCER EPIDEMI-OLOGY WORKING GROUP. Childhood cancerincidence and survival in Spain. Ann Oncol.2010; 21:103-10. FI: 5,647. 1r quartil.GATTA G, ZIGON G, AARELEID T, ARDANAZ E, BIELSKA-LASOTA M, GALCERAN J, GÓźDź S, HAKULINENT, MARTINEZ-GARCIA C, PLESKO I, ZAKELJ MP,RACHTAN J, TAGLIABUE G, VERCELLI M, FAIVREJ. Patterns of care for European colorectalcancer patients diagnosed 1996-1998:a EUROCARE high resolution study. ActaOncol. 2010; 49:776-83. FI: 2,265. 3rquartil.RODRÍGUEZ M, TORRES A, BORRÀS J, SALVAT M,GUMÀ J. CORRESPONDENCE: GUMÀ J. Largegenomic rearrangements in mutationnegativeBRCA families: a population-basedstudy. Letter to the Editor. Clin Genetsetembre 2010; 78:405-7. FI: 3,304. 2nquartil.MARCOS-GRAGERA R, VILAR-COROMINA N, GALCE-RAN J, BORRÀS J, CLÈRIES R, RIBES J, GISPERTR, IZQUIERDO A, BORRÀS JM. Rising trendsin incidence of cutaneous malignant melanomaand their future projections in Catalonia,Spain: increasing impact or futureepidemic? J Eur Acad Dermatol Venereol2010; 24:1083-8. FI: 2,787. 1r quartil.SANZ J, RAMÓN Y CAJAL T, TORRES A, DARDER E,GADEA N, VELASCO A, FORTUNY D, LÓPEZ C, FI-SAS D, BRUNET J, ALONSO MC, BALMAÑA J. Uptakeof predictive testing among relatives ofBRCA1 and BRCA2 families: a multicenterstudy in northeastern Spain. Fam Cancer.2010; 9:297-04. FI: 2,189. 3r quartil.BORRÀS E, PINEDA M, BLANCO I, JEWETT EM, WANGF, TEULÉ A, CALDÉS T, URIOSTE M, MARTÍNEZ-BOUZAS C, BRUNET J, BALMAÑA J, TORRES A,RAMÓN Y CAJAL T, SANZ J, PÉREZ-CABORNEROL, CASTELLVÍ-BEL S, ALONSO A, LANAS A,GONZÁLEZ S, MORENO V, GRUBER SB, ROSEN-BERG NA, MUKHERJEE B, LÁZARO C, CAPELLÁG. MLH1 founder mutations with moderatepenetrance in Spanish Lynch syndromefamilies. Cancer Res. 2010; 70:7379-91.FI: 7,543. 1r quartil.GUIX B, LEJÁRCEGUI JA, TELLO JI, ZANÓN G, HEN-RÍQUEZ I, FINESTRES F, MARTÍNEZ A, FERNANDEZ-IBIZA J, QUINZAÑOS L, PALOMBO P, ENCINAS X,GUIX I. Exeresis and brachytherapy as salvagetreatment for local recurrence afterconservative treatment for breast cancer:results of a ten-year pilot study. Int J RadiatOncol Biol Phys. 2010; 78:804-10. FI:4,592. 1r quartil.INTERNATIONAL PROGNOSTIC FACTORS STUDY GROUP,LORCH A, BEYER J, BASCOUL-MOLLEVI C, KRA-MAR A, EINHORN LH, NECCHI A, MASSARD C,DE GIORGI U, FLÉCHON A, MARGOLIN KA, LOTZJP, GERMA LLUCH JR, POWLES T, KOLLMANNS-BERGER CK (GUMÀ J). Prognostic factors inpatients with metastatic germ cell tumorswho experienced treatment failure withcisplatin-based fi rst-line chemotherapy. JClin Oncol. 2010; 28:4906-11. FI: 17,793.1r quartil.97